首页|瑞舒伐他汀联合氯吡格雷治疗冠心病不稳定型心绞痛的有效性探讨

瑞舒伐他汀联合氯吡格雷治疗冠心病不稳定型心绞痛的有效性探讨

扫码查看
目的 探讨对于冠状动脉粥样硬化性心脏病(简称冠心病)不稳定心绞痛患者实施瑞舒伐他汀联合氯吡格雷治疗的有效性及安全性.方法 选取2021年3月—2022年12月东台市中医院收治的116例冠心病不稳定心绞痛患者为研究对象,均实施常规药物(如阿司匹林肠溶片+酒石酸美托洛尔+低分子肝素)治疗,以随机摸球法将其分为两组,各58例.对照组在常规处理后联合辛伐他汀,治疗组在常规处理后给予瑞舒伐他汀联合氯吡格雷治疗.对比两组治疗有效性、心绞痛发作情况、血脂指标和安全性.结果 治疗组治疗总有效率(96.55%)高于对照组(86.21%),差异有统计学意义(χ2=3.940,P<0.05).经过6周治疗后,治疗组心绞痛发作频率及持续时间均少于对照组,差异有统计学意义(P均<0.05);治疗组血脂指标中三酰甘油、总胆固醇及低密度脂蛋白胆固醇水平明显低于对照组低,高密度脂蛋白胆固醇水平显著高于对照组,差异有统计学意义(P均<0.05).治疗组不良反应发生率显著低于对照组,差异有统计学意义(P<0.05).结论 对冠心病不稳定型心绞痛患者以瑞舒伐他汀联合氯吡格雷进行治疗,能减少心绞痛发作情况,缩短发作持续时间,控制血脂水平,同时也具有一定的安全性,可减少不良反应.
Efficacy of Rosuvastatin Combined with Clopidogrel in the Treatment of Unstable Angina Pectoris of Coronary Heart Disease
Objective To investigate the efficacy and safety of rosuvastatin combined with clopidogrel in the treatment of unstable angina pectoris in patients with coronary atherosclerotic heart disease(CHD).Methods 116 cases of un-stable angina patients with coronary heart disease admitted to Dongtai Hospital of Traditional Chinese Medicine from March 2021 to December 2022 were selected for the study,all of which were treated with conventional drugs(such as aspirin enteric-coated tablets + metoprolol tartrate + low molecular heparin),and were divided into 2 groups by ran-domized feeler-ball method,with 58 cases in each group.The control group were given simvastatin combined with clopidogrel after conventional treatment,and the treatment group were given rosuvastatin combined with clopidogrel af-ter conventional treatment.Comparing the effectiveness of treatment,angina attack,lipid index,and safety of the two groups.Results The effectiveness of the treatment group was 96.55%higher than 86.21%in the control group,and the difference was statistically significant(χ2=3.940,P<0.05).After 6 weeks of treatment,the frequency and duration of angina attacks in the treatment group were significantly less than those in the control group,and the differences were statistically significant(both P<0.05).After treatment,the levels of triacylglycerol,total cholesterol and low-density lipoprotein cholesterol in the treatment group were significantly lower than those in the control group,and the level of high-density lipoprotein cholesterol was significantly higher than that in the control group,the differences were statistically significant differences(all P<0.05).The incidence of adverse reactions in the treatment group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Treatment of patients with unstable angina in coronary artery disease with rosuvastatin combined with clopidogrel therapy canreduce angina attacks,shorten duration,control lipid levels,and also has a certain degree of safety and canreduce adverse reactions.

RosuvastatinClopidogrelCoronary heart diseaseUnstable typeAngina pectorisEffectivenessSecurity

黄小春

展开 >

东台市中医院心血管内科,江苏盐城 224200

瑞舒伐他汀 氯吡格雷 冠心病 不稳定型 心绞痛 有效性 安全性

2024

系统医学

系统医学

ISSN:
年,卷(期):2024.9(6)
  • 20